Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dose Finding Phase IIb Study of Bavisant to Evaluate Its Safety and effiCacy in treAtment of exceSsive Daytime sleePiness (EDS) in PARkinson's Disease (PD).

NCT03194217 is registered in ClinicalTrials.gov with BenevolentAI Bio as lead sponsor.

NCT NCT03194217
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03194217 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dose Finding Phase IIb Study of Bavisant to Evaluate Its Safety and effiCacy in treAtment of exceSsive Daytime sleePiness (EDS) in PARkinson's Disease (PD).
Lead sponsor
BenevolentAI Bio
Phase
Phase 2
Overall status
Completed
Start date
November 10, 2017
Completion date
May 28, 2019
Enrollment
244 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

excessive daytime sleepiness, parkinson disease